Cortex to Host Conference Call to Discuss the Positive Progress Obtained During AMPAKINE CX717 Phase I Studies; Call Scheduled for Wednesday, September 29, 2004.IRVINE, Calif. -- Cortex Pharmaceuticals, Inc. (AMEX AMEX See: American Stock Exchange : COR) has scheduled a conference call to discuss the encouraging results from the AMPAKINE(R) CX717 Phase I studies, other AMPAKINE related information and upcoming clinical milestones. The call is scheduled for Wednesday, September 29, 2004 at 1:00 P.M. EST. Participants are asked to call the following numbers 5-10 minutes prior to the starting time: --From the U.S. and Canada: 1-800-289-0493 --International: 913-981-5510 A replay will be available for 30 days after the call by dialing 1-888-203-1112 (US and Canada) or 719-457-0820 (International) and entering access code 923456 when prompted. For more information, call: Jane Lin or Dian Griesel, Ph.D. at The Investor Relations Investor relations The process by which the corporation communicates with its investors. Group, Inc. Phone: 212-825-3210. About Cortex Pharmaceuticals: Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. The Company is pioneering a class of proprietary pharmaceuticals called AMPAKINE compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. . Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain's neurotransmitter system. These imbalances may be improved by using the AMPAKINE technology. Cortex has alliances with N.V. Organon or·ga·non or or·ga·num n. pl. or·ga·nons or or·ga·nums or or·ga·na 1. An organ. 2. A set of principles for use in scientific investigation. organon pl. organa [Gr.] organ. for the treatment of schizophrenia The concept of a cure as such in the treatment of schizophrenia remains controversial, as there is no consensus on the definition of "treatment" in the case of schizophrenia, although some criteria for the remission of symptoms have recently been suggested. and depression and with Les Laboratoires Servier for the development of AMPAKINE compounds to treat the neurodegenerative effects associated with aging and disease, including Mild Cognitive Impairment mild cognitive impairment (MCI), n memory loss generally associated with aging; does not affect normal independent functioning of an individual. , Alzheimer's disease and Anxiety Disorders. (http://www.cortexpharm.com/) |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion